Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial

OBJECTIVES: Tenapanor is a first-in-class, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger NHE3. This study assessed the efficacy and safety of tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C). METHODS: In this phase 2, double-blind stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Chey, William D, Lembo, Anthony J, Rosenbaum, David P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Functional GI Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418559/
https://www.ncbi.nlm.nih.gov/pubmed/28244495
http://dx.doi.org/10.1038/ajg.2017.41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418559/
https://www.ncbi.nlm.nih.gov/pubmed/28244495
http://dx.doi.org/10.1038/ajg.2017.41

Ejemplares similares